FIsetin to Reduce Senescence and Mobility ImpairmenT in PAD: The FIRST Pilot Randomized Trial

FIsetin to Reduce Senescence and mobility impairmenT in PAD: the FIRST Pilot Randomized Trial. University of Kentucky Scope of Work Co-Principal Investigators: Charlotte Peterson PhD and Kate Kosmac, PhD As a site Co-Principal Investigator in the FIRST Study (Northwestern University, PI: Mary McGrae McDermott, MD), Dr. Peterson’s laboratory will measure quantities of senescent associated secretory phenotype (SASP) markers in adipose tissue and skeletal muscle specimens at the RNA level. A total of approximately 66 adipose tissue and 26 muscle samples will be analyzed. For immunohistochemistry, approximately 26 muscle samples will be collected and analyzed by Dr. Kosmac (Co-Principal Investigator) for extracellular matrix collagens I & III, muscle fiber size (cross-sectional area), endothelial cell abundance and abundance of senescence-associated β-gal (SAβG) positive cells.